Summary:
This trial will be a adaptive, open label, single and/or multiple oral dose, safety, tolerability, food effect trial of CVL-751 in subjects with Parkinson's disease. Part 1 is a placebo-controlled, single dose cohort intended for assessment of safety and tolerability. In case of intolerable AEs, Part 2 would proceed as a multiple dose titration trial to achieve a 15 mg once daily dose while maintaining L-Dopa treatment (Part 2A).
Qualified Participants Must:
• Be 45-75 years old
•
Diagnosed Parkinson's disease
•
Be on a stable dose of levodopa
Qualified Participants May Receive:
Compensation for time and travel